Using interferon-gamma and donor lymphocyte infusion to treat relapsed myeloid cancers after stem cell transplants
Official title: Phase 2 Study of Interferon-Gamma and Donor Lymphocyte Infusion for the Treatment of Relapsed Myeloid Malignancies after Allogeneic Stem Cell Transplantation
Funded at University of Pittsburgh at Pittsburgh · NIH-11097692 · Data updated 2026-11-12
This study is looking at a new treatment for people who have had a relapse of acute myeloid leukemia or myelodysplastic syndrome after a stem cell transplant, testing whether combining two therapies can help boost the immune system to fight the cancer better and improve survival and remission times.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | September 15, 2024 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $882,247 |
| NIH project number | 1R01FD008187-01A1 |
| Project ID | NIH-11097692 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who have relapsed AML or MDS following allogeneic stem cell transplantation.
✕Less likely to help
Patients who have not undergone stem cell transplantation or those with other types of leukemia may not benefit from this research.
What this research studies
This research investigates a treatment approach for patients who have experienced a relapse of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after undergoing allogeneic stem cell transplantation. The study will evaluate the effectiveness of combining interferon-gamma with donor lymphocyte infusion to enhance the body's immune response against leukemia cells. By analyzing patient outcomes compared to historical data, the research aims to determine if this combination therapy can improve survival rates and remission duration for affected patients.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that significantly improves survival and quality of life for patients with relapsed myeloid malignancies.
How similar studies have gone: Previous studies have shown promising results with similar approaches, indicating potential for success in this phase 2 trial.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Ito, Sawa — University of Pittsburgh at Pittsburgh
- Study coordinator: Ito, Sawa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.